1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial Intelligence (AI) based screening tool for AMD.
No linked publications found in PubMed
Inclusion Criteria: * Participants greater than or equal to 50 years of age at time of signing Informed Consent Form * Willing to comply with all study procedures and sign the Informed Consent Form (ICF) * Individuals with normal healthy eyes or diagnosed with any stage of Age-Related Macular Degeneration (treatment naïve patients with early, intermediate, or late AMD). The diagnosis and eligibility review will be confirmed by Central Reading Center. Exclusion Criteria: * Therapeutic treatment for any type of AMD, in either eye. Supplements, such as AREDS2 formula, are allowed. * Unable to acquire adequate quality images, as evaluated by the Central Reading Center * Severe vision loss requiring urgent surgery * Contraindicated for acquiring retinal images due to narrow anterior chamber angles or hypersensitivity to light * A systemic or ocular condition that in the opinion of the Investigator would preclude participation in the study * Unwilling to sign informed consent form * Currently or previously enrolled in an interventional AMD clinical trial